Who We Are

Progenra, Inc. is pursuing novel approaches to therapeutic intervention of the ubiquitin pathway based upon proprietary technology encompassed under its UbiPro™ Drug Discovery Platform. Key discoveries and unsurpassed know-how are creating new opportunities for ameliorating diseases in a number of therapeutic areas.

Progenra’s multi-faceted approach addresses the known heterogeneity of the sites at which enzymes of the ubiquitin pathway interact with their substrates under physiological conditions. Progenra's scientists determine the best assay(s) suited for targets of interest and then implement them in our drug discovery operations.